Biovian is excited to announce participation in two major industry events to start 2024. Our representatives are ready to meet you at the Advanced Therapy Week 2024 in Miami and PepTalk 2024 in San Diego, …
Biovian, a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the appointment of Monica Lazaro as US East Coast Business Development Director, effective January 2nd, 2024. Monica will play a …
Biovian is delighted to announce the successful completion of a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion. The package will be used …
We are delighted to tell you that Biovian will be participating in the Biotech Week Boston on September 18-21, 2023! You can meet our team at the concurrent BPI/Cell & Gene Therapy Manufacturing & Commercialization …
We are thrilled to announce that Biovian will be participating in the 15th Annual Bioprocessing Summit in Boston, scheduled to take place from August 14-17, 2023. This premier event brings together industry leaders and experts …
Biovian is gearing up to exhibit at the highly anticipated BIO International Convention in June 5-8, 2023. This premier global event will bring together pioneers, innovators, and thought leaders from around the world to explore …
Biovian will be exhibiting at the 26th Annual ASGCT Meeting held in Los Angeles, in May 16-20, 2023. Meet the Biovian representatives Magnus Gustafsson CBO, Eero Mustalahti Head of Business Development and Taru Värri Marketing …
Biovian is looking forward to participating in the BIO International Convention on June 13th-16th in San Diego. #BIO2022 is back in person. Biovian representatives, CBO Magnus Gustafsson and Head of Business Development Eero Mustalahti are …
Viral contaminations are rare events in biopharmaceutical manufacturing, but regulatory agencies expect all biologics to undergo viral clearance testing to mitigate the risk of contamination [1, 2]. Therapies based on viral vectors have a small …
The article discusses the reasons behind the growing need for viral vectors and how Biovian, as a CDMO has taken actions to solve the manufacturing bottleneck. Antti Nieminen, CEO of Biovian: “The majority of Biovian’s customers …
